[1] Zheng RS, Zhang SW, Zeng HM, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2(1): 1-9. [2] 周晖, 刘昀昀, 罗铭, 等. 《2024 NCCN子宫颈癌临床实践指南(第1版)》更新解读[J]. 中国实用妇科与产科杂志, 2023, 39(11): 1119-1121. DOI: 10.19538/j.fk2023110113. Zhou H, Liu YY, Luo M, et al. Updating and Interpretation of "NCCN guidelines version 1. 2024 cervical cancer"[J]. Chin J Pract Gynecol Obstet, 2023, 39(11): 1119-1121. DOI: 10.19538/j.fk2023110113. [3] Cibula D, Rosaria Raspollini M, Planchamp F, et al. ESGO/ESTRO/ESP guidelines for the management of patients with cervical cancer - update 2023[J]. Radiother Oncol, 2023, 184: 109682. [4] Onal C, Arslan G, Topkan E, et al. Comparison of conventional and CT-based planning for intracavitary brachytherapy for cervical cancer: target volume coverage and organs at risk doses[J]. J Exp Clin Cancer Res, 2009, 28(1): 95. [5] Shin KH, Kim TH, Cho JK, et al. CT-guided intracavitary radiotherapy for cervical cancer: comparison of conventional point A plan with clinical target volume-based three-dimensional plan using dose-volume parameters[J]. Int J Radiat Oncol Biol Phys, 2006, 64(1): 197-204. [6] Holschneider CH, Petereit DG, Chu C, et al. Brachytherapy: a critical component of primary radiation therapy for cervical cancer: from the society of gynecologic oncology (SGO) and the American brachytherapy society (ABS)[J]. Brachytherapy, 2019, 18(2): 123-132. [7] Nomden CN, De Leeuw AAC, Moerland MA, et al. Clinical use of the Utrecht applicator for combined intracavitary/interstitial brachytherapy treatment in locally advanced cervical cancer[J]. Int J Radiat Oncol Biol Phys, 2012, 82(4): 1424-1430. [8] Dimopoulos JCA, Kirisits C, Petric P, et al. The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer: clinical feasibility and preliminary results[J]. Int J Radiat Oncol Biol Phys, 2006, 66(1): 83-90. [9] Wang Y, Ye WJ, Du LH, et al. Dose-volume parameters and clinical outcome of CT-guided free-hand high-dose-rate interstitial brachytherapy for cervical cancer[J]. Chin J Cancer, 2012, 31(12): 598-604. [10] Cunha JAM, Mellis K, Sethi R, et al. Evaluation of PC-ISO for customized, 3D printed, gynecologic 192Ir HDR brachytherapy applicators[J]. J Applied Clin Med Phys, 2015, 16(1): 246-253. [11] 南贤秀, 张洪明, 侯彦杰, 等. 3D打印技术在放疗中的应用与进展[J]. 国际放射医学核医学杂志,2020,44(1):65-70. Nan XX, Zhang HM, Hou YJ, et al. Application and progress of 3D printing technology in radiotherapy[J]. Int J Radiat Med Nucl Med, 2020, 44(1): 65-70. [12] 张永侠, 袁香坤, 苗珺珺, 等. 3D打印模板应用于局部晚期宫颈癌后装放疗的剂量学研究[J]. 中华放射医学与防护杂志,2020,40(7):519-523. Zhang YX, Yuan XK, Miao JJ, et al. Dosimetric analysis of 3D-printed minimally invasive-guided template in the brachytherapy treatment of locally advanced cervical cancer[J]. Chin J Radiol Med Prot, 2020, 40(7): 519-523. [13] 王彬冰, 郑光浩, 张翔, 等. 经阴道3D打印个体化模板在宫颈癌后装治疗中的应用价值研究[J]. 中华放射肿瘤学杂志,2020,29(4):283-288. Wang BB, Zheng GH, Zhang X, et al. Application value of individualized 3D-printed vaginal template for cervical cancer brachytherapy[J]. Chin J Radiat Oncol, 2020, 29(4): 283-288. [14] Yuan XK, Zhang YX, Cui MM, et al. Dosimetry comparison between a 3D printed minimally invasive guidance template and free implantation in the brachytherapy treatment of postoperative recurrent cervical carcinoma[J]. Cancer Manag Res, 2019, 11: 5013-5018. [15] 赵志鹏, 管薇, 赵红福, 等. 3D打印模板辅助标准化施源器在IIIB期宫颈癌影像引导自适应近距离治疗中的应用[J]. 中华放射肿瘤学杂志,2020,29(8):661-665. Zhao ZP, Guan W, Zhao HF, et al. Application of 3D printing technology-assisted standardized applicator in image-guided adaptive brachytherapy of stage Ⅲ B cervical cancer[J]. Chin J Radiat Oncol, 2020, 29(8): 661-665. [16] 张菁, 闫庆倩, 杨声. 2020年南京市放射诊疗资源配置现况调查与分析[J]. 中国辐射卫生,2022,31(1):27-32. Zhang J, Yan QQ, Yang S. An investigation and analysis of the status of radiological diagnosis and treatment resource allocation in Nanjing, China, 2020[J]. Chin J Radiol Health, 2022, 31(1): 27-32. [17] Wu YQ, Zhu BQ, Han JJ, et al. A comparative dosimetric study of cervical cancer patients with para-aortic lymph node metastasis treated with volumetric modulated arc therapy vs. 9-field intensity-modulated radiation therapy[J]. Ann Transl Med, 2019, 7(22): 675. [18] HAIE-Meder C, Pötter R, Van Limbergen E, et al. Recommendations from gynaecological (GYN) GEC-ESTRO working group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV[J]. Radiother Oncol, 2005, 74(3): 235-245. [19] Prescribing, recording, and reporting brachytherapy for cancer of the cervix[J]. J ICRU, 2016, 13(1/2): 1-258. DOI: 10.1093/jicru/ndw027. [20] Schwartz LH, Litière S, De Vries E, et al. RECIST 1.1-update and clarification: from the RECIST committee[J]. Eur J Cancer, 2016, 62: 132-137. [21] Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC)[J]. Int J Radiat Oncol Biol Phys, 1995, 31(5): 1341-1346. [22] Tomasevic A, Plesinac Karapandzic V, Stojanovic Rundic S, et al. 3D MRI-based evaluation of the 2D brachytherapy planning in patients with advanced cervical cancer: an analysis of the delivered dose[J]. J BUON, 2020, 25(1): 108-115. [23] 谭华艳, 卢敏, 邓烨, 等. 宫颈癌三维后装近距离治疗技术研究进展[J]. 中国辐射卫生,2021,30(3):371-376. Tan HY, Lu M, Deng Y, et al. Advances on the technique of three-dimensional intracavitary brachytherapy for cervical cancer[J]. Chin J Radiol Health, 2021, 30(3): 371-376. [24] 朱云云, 傅志超, 陈杰, 等. MRI影像与CT影像勾画宫颈癌三维腔内后装放疗靶区体积的比较[J]. 国际放射医学核医学杂志,2020,44(4):231-235. Zhu YY, Fu ZC, Chen J, et al. Comparison of the target volumes delineated by MRI and CT images in patients with cervical cancer who received 3D intracavitary brachytherapy[J]. Int J Radiat Med Nucl Med, 2020, 44(4): 231-235. [25] Kuipers T, Hoekstra C, Van 'T Riet A, et al. HDR brachytherapy applied to cervical carcinoma with moderate lateral expansion: modified principles of treatment[J]. Radiother Oncol, 2001, 58(1): 25-30. [26] Aggarwal L, Mourya A, Choudhary S. Evolution of brachytherapy applicators for the treatment of cervical cancer[J]. J Med Phys, 2021, 46(4): 231. [27] 张永侠, 袁香坤, 史福敏, 等. 局部晚期宫颈癌腔内放疗联合组织间插植的剂量学研究[J]. 中华放射医学与防护杂志,2017,37(12):919-923. Zhang YX, Yuan XK, Shi FM, et al. A dosimetric analysis of combined intracavitary/interstitial brachytherapy for locally advanced cervical cancer[J]. Chin J Radiol Med Prot, 2017, 37(12): 919-923. [28] Wright JD, Matsuo K, Huang YM, et al. Prognostic performance of the 2018 international federation of gynecology and obstetrics cervical cancer staging guidelines[J]. Obstet Gynecol, 2019, 134(1): 49-57. [29] 刘萍, 黎志强, 柳攀, 等. FIGO 2018子宫颈癌分期Ⅲ期各亚期设置合理性探讨[J]. 中国实用妇科与产科杂志,2021,37(6):669-672. Liu P, Li ZQ, Liu P, et al. Rationality of stage Ⅲ substaging in FIGO 2018 staging of cervical cancer[J]. Chin J Pract Gynecol Obstet, 2021, 37(6): 669-672. [30] Pötter R, Dimopoulos J, Georg P, et al. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer[J]. Radiother Oncol, 2007, 83(2): 148-155. [31] Wang F, Bu LY, Wu Q, et al. Comparison of computed tomography- and magnetic resonance imaging-based target delineation for cervical cancer brachytherapy[J]. J Contemp Brachytherapy, 2020, 12(4): 367-374. [32] Hellebust TP. Place of modern imaging in brachytherapy planning[J]. Cancer Radiother, 2018, 22(4): 326-333. [33] Wachter-Gerstner N, Wachter S, Reinstadler E, et al. The impact of sectional imaging on dose escalation in endocavitary HDR-brachytherapy of cervical cancer: results of a prospective comparative trial[J]. Radiother Oncol, 2003, 68(1): 51-59.